
Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) rose sharply in pre-market trading after the company announced it will receive a $5 million investment from Ocugen as part of a merger with Ocugen’s subsidiary OrthoCelix.
Carisma Therapeutics shares jumped 133.4% to $0.5019 in the pre-market trading session.